Buprenorphine Market Size

Buprenorphine Market size was valued at USD 5.44 billion in 2023 and is expected to exceed USD 31.27 billion by 2036, registering over 14.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of buprenorphine is assessed at USD 6.07 billion.

The growth of the market can be attributed to the growing prevalence of chronic pain disorders, increasing occurrence of cancer. According to the World Health Organization (WHO), cancer is the leading cause of deaths worldwide, accounting to about 10 million deaths in the year 2020. In addition to these, escalating government investments in healthcare in developed nations and rising usage of buprenorphine patches as an effective treatment mode is also anticipated to drive market growth in the coming years. Furthermore, the growing dependency on painkillers has led to opioid addiction to many people around the world, which in turn is projected to provide lucrative opportunities to significantly raise the demand for buprenorphine in the near future.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of buprenorphine is assessed at USD 6.07 billion.

Buprenorphine Market size was valued at USD 5.44 billion in 2023 and is expected to exceed USD 31.27 billion by 2036, registering over 14.4% CAGR during the forecast period i.e., between 2024-2036. Increasing occurrence of chronic pain disorders and rising healthcare expenditure in developed nations will propel the market growth.

North America is set to account for largest revenue share by 2036, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region.

The major players in the market are The Siegfried Group, LLP, Johnson Matthey Group, Purdue Pharma LP, Pharmaforce Inc., Hikma Pharmaceuticals PLC, and others.

Buprenorphine Market Size